Cat No. 76-J32

WP1066


10mg



For research purposes only

WP1066 is a Janus kinase (Jak) 2 inhibitor. It works by degrading the Jak2 protein, thus blocking its downstream signal transducer and activator of transcription (STAT) and phosphoinositide-3-kinase pathways to result in the activation of the caspase pathway. The Jak/STAT pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals. In mammals, it is the principal signaling mechanism for a wide array of cytokines and growth factors. WP1066 also acts as an immune adjuvant by inducing proliferation of effector T cells and upregulating CD86 and CD80.

TECHNICAL INFORMATION



STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in \geq 71mg/mL of DMSO.

Other Names: (S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamine

Chemical Formula: C₁₇H₁₄BrN₃O

CAS Number: 857064-38-1

PubChem Substance ID: 11210478

Molecular Weight: 356.22

Purity: >99%

Appearance: Off White Solid

Solubility: DMSO

IC₅₀: JAK2= 2.3μm, Stat3= 2.43μm

REFERENCES

- Hatiboglu, M.A., et al (2012). The tumor microenvironment expression of the p-Stat3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int. J. Cancer. 131:8-17.
- Horiquchi, A., et al (2010). Stat3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br. J. Cancer. 102-1592-9.
- 3. Verstovsek, S., et al (2008). WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin. Cancer Res. 14:788-96.

